|
 The announcement comes at a critical time as Sanofi is working on
two vaccine projects to protect against COVID-19, the illness caused
by the new coronavirus.
Loew, who has been with Sanofi for almost seven years and in charge
of the vaccines unit since 2016, will fill a management vacuum at
Ipsen, which has been struggling to find a new CEO since the
departure of David Meek at the end of last year.
His main task will be to boost Ipsen's pipeline, including on the
back of deals or acquisitions in the fields of oncology, rare
diseases and neurosciences, as well as to deliver on financial
results.
The company is looking to strengthen its portfolio to offset the
long-term generic threat to its top-selling cancer treatment
Somatuline.
Ipsen lowered its 2022 outlook in February to take into account
setbacks in trials of bone disorders product palovarotene, inherited
last year from the $1.3 billion acquisition of Canadian biotech
company Clementia Pharmaceuticals.
In March, Ipsen said it was also suspending its 2020 guidance as a
result of the coronavirus pandemic.
[to top of second column] |
Sanofi said Loew would be replaced by Thomas Triomphe as head of vaccine unit
Sanofi Pasteur. Like Loew, Triomphe will be sitting on Sanofi's executive
committee.
It made three other appointments at its executive committee, naming Julie Van
Ongevalle head of consumer healthcare, Arnaud Robert chief digital officer and
Natalie Bickford chief people officer.
The moves were expected as Sanofi hired a new CEO, Paul Hudson, in September
last year and set out a new roadmap three months later.
"We need leaders who come to Sanofi with a fresh perspective as well as leaders
who have grown up within the company," Hudson said.
(Reporting by Matthias Blamont; Editing by Nick Tattersall)
[© 2020 Thomson Reuters. All rights
reserved.] Copyright 2020 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |
